{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-009748","form_type":"8-K","ticker":"AVR","cik":"0002011514","company_name":"Anteris Technologies Global Corp.","filed_at":"2025-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.791992+00:00","generated_at":"2026-05-24T09:20:54.909869+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Anteris DurAVR THV reports zero PPM at one year in small annuli patients","bullets":["One-year hemodynamic data: EOA 2.1±0.2 cm², mean gradient 8.6±2.6 mmHg, DVI 0.58 (n=65).","Zero prosthesis-patient mismatch (PPM) in small annuli patients; commercial valves report 11-35% PPM.","No valve or cardiovascular related mortality at one year; consistent safety profile.","Data to support planned IDE submission to FDA for DurAVR THV pivotal study.","Results presented at Sydney Valves late-breaking clinical trial session on March 21, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-009748","json":"https://secwatch.observer/filing/0001140361-25-009748.json","markdown":"https://secwatch.observer/filing/0001140361-25-009748.md","text":"https://secwatch.observer/filing/0001140361-25-009748.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2011514/000114036125009748/0001140361-25-009748-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2011514/000114036125009748/ef20045825_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T09:20:54.909869+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}